BrickBio Achieves Stable Cell Line in Record Timeframe: 5x Faster with 7x Enhanced Production
BOSTON, February 7, 2023 /PRNewswire/ -- BrickBio Highlights Unique Advantages from the Proprietary "VADER" System, published on Dec 22,...
top of page
Search
jamesitalia
- Apr 25, 2022
- 3 min
BrickBio Unveils Powerful Engineered RNA Therapeutic Modification Platform at AACR 2022
BOSTON, April 25, 2022 /PRNewswire/ -- BrickBio Highlights Powerful Advantage of the Company's BrickADCs™, Protein Origami™, and...
639 views0 comments
jamesitalia
- Nov 2, 2021
- 2 min
BrickBio Announces Rapid V2, eCLIC™, Chemistry and Cytokine External Partner Collaboration
BOSTON, Nov. 2, 2021 /PRNewswire/ -- BrickBio, the leader in site-specific bioconjugation, announced a rapid next-generation conjugation...
553 views0 comments
jamesitalia
- Oct 27, 2021
- 3 min
World's First Antibody Drug Conjugate (ADC) Rapid Predictive SiteSelect™ Panel Launched
BOSTON, Oct. 26, 2021 /PRNewswire/ -- A Rapid Predictive Site-Selection Panel for ADC-Linker-Payload Optimization BrickBio, the leader in...
404 views0 comments
BrickBio
- Jan 29, 2021
- 2 min
BrickBio Creates Novel Class of Bispecific Antibody Drug Conjugate and Receives Green Light
BOSTON, Jan. 19, 2021 /PRNewswire/ -- The leader in site specific bioconjugation and DAR (drug to antibody ratio) optimization in...
607 views0 comments
BrickBio
- Jan 29, 2021
- 2 min
BrickBio Enters into Antibody Drug Conjugate (ADC) Co-Development Partnership with Large Pharma
BOSTON, Jan. 6, 2021 /PRNewswire/ -- BrickBio, the leading company in site-specific bioconjugation for improved therapeutics, has signed...
606 views0 comments
BrickBio
- Nov 10, 2020
- 3 min
BrickBio Announces Data on First Preclinical Antibody for Breast and Gastric Cancer
The company is developing biologics across three internal programs BOSTON, Nov. 10, 2020 /PRNewswire/ -- The leading company in...
595 views0 comments
BrickBio
- Sep 2, 2020
- 2 min
BrickBio Validates Its Novel Therapeutic Conjugation Platform at Commercial Scale
BrickBio has made robust its novel site-specific conjugation process of inserting unnatural amino acids at any site within a protein or...
251 views0 comments
BrickBio
- Jan 30, 2020
- 2 min
BrickBio Expands Space to Accommodate Pharma Partnerships and Pipeline Development
BOSTON, Jan. 22, 2020 /PRNewswire/ -- BrickBio Inc., the leading company in site specific, single and multi-site bioconjugation of...
413 views0 comments
BrickBio
- Nov 8, 2019
- 3 min
Abcam & BrickBio announce partnership to incorporate conjugation-ready sites across Abcam portfolio
- BrickBio’s technology enables efficient placement of unnatural amino acids into recombinant antibodies at specific sites - Together,...
607 views0 comments
BrickBio
- Oct 18, 2019
- 2 min
BrickBio Presents Novel Conjugation Chemistry & Unveiled Protein Therapeutic Program at World ADC
Boston, Massachusetts – BrickBio, a protein engineering company formed out of the Chatterjee Lab at Boston College and backed by Tiger...
393 views0 comments
BrickBio
- Jun 13, 2019
- 2 min
Dr. James Italia Joins BrickBio as Vice President of Commercial Development
Boston, Massachusetts – BrickBio, the Tiger Gene backed protein and antibody modification company, announced today that Dr. James Italia,...
664 views0 comments
BrickBio
- Apr 12, 2019
- 1 min
BrickBio Obtains Exclusive License to “Pan Epitope” Site-Specific Antibody and Protein Modification
Boston, Massachusetts - BrickBio, a company formed out of Tiger Gene has obtained a worldwide exclusive license, from Boston College, to...
494 views0 comments
bottom of page